|
| Primary information |
|---|
| ID | 10858 |
| Therapeutic ID | Th1220 |
| Protein Name | Brodalumab |
| Sequence | NA
|
| Molecular Weight | 1,44,000 |
| Chemical Formula | C6372H9840N1712O1988S52 |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | NA |
| Description | Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. |
| Indication/Disease | Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. |
| Pharmacodynamics | Increase in the level of IL-17 due to blocking of its receptors. |
| Mechanism of Action | Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| 4.62 L. |
| Clearance | 0.223 L/day. |
| Categories | Antineoplastic and Immunomodulating Agents |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | The risk or severity of adverse effects can be increased with combination of drugs like BCG, Denosumab, Fingolimod, G17DT, GI-5005, INGN 201, INGN 225, Leflunomide, Natalizumab, Pimecrolimus. |
| Target | Interleukin 17 receptor A |
| Brand Name | Siliq |
| Company | NA |
| Brand Description | NA |
| Prescribed For | SILIQâ„¢ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. |
| Chemical Name | NA |
| Formulation | Each SILIQ single-dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8. |
| Physical Appearance | sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution |
| Route of Administration | Subcutaneous |
| Recommended Dosage | The recommended SILIQ dose is 210 mg administered by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks. |
| Contraindication | SILIQ is contraindicated in patients with Crohn’s disease because SILIQ may cause worsening of disease |
| Side Effects | Suicidal Ideation and Behavior, Infection and Crohn’s Disease |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |